AzTrials
AzTrials

Recurrent GlioblastomaPhase 1/2NCT03750071

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

A Phase 1/2 study testing VXM01 and Avelumab in people with Recurrent Glioblastoma, run by Vaximm GmbH at 2 sites in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Recurrent Glioblastoma
What is being tested?
VXM01 and Avelumab
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
2 sitesGermany
Study dates
21 Nov 2018to 31 Dec 2022
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects who are able to understand and follow instructions during the trial
  • Ability and willingness to give written informed consent, signed and dated
  • Male or female subjects. Female subjects must be post-menopausal for at least 2 years or surgically sterile
  • Age ≥18 years
  • Histologically diagnosed intracranial supratentorial malignant glioma (glioblastoma WHO Grade IV)
  • Evidence of tumor progression by RANO criteria following at least one prior therapy regimen that must have contained radiation and chemotherapy with temozolomide, as measured by MRI
Show all 17Show fewer
  • Radiotherapy must have been completed at least 3 months prior to the inclusion visit
  • Candidates for a tumor reoperation (for the resectable arm [n=6] only)
  • Neurosurgical intervention should be postponable for 30 days
  • Adequate bone marrow function including: Absolute neutrophil count (ANC) ≥1,500/mm3 or ≥1.5 x 109/L; Platelets ≥ 100,000/mm3 or ≥100 x 109/L; Hemoglobin ≥ 9 g/dL (may have been transfused); INR <1.5x ULN. Subjects with documented benign cyclical neutropenia are allowed if WBC count is ≥ 1.5 × 109/L with absolute neutrophil count ≥ 1.0 × 109/L and appropriate hematology parameters: leukocytes ≥4.0 x 109 / L, lymphocytes ≥0.6 x 109/L
  • Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal range (ULN), an aspartate aminotransferase (AST), level ≤ 2.5 × ULN, and an alanine aminotransferase (ALT) level ≤ 2.5 × ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels ≤ 5 × ULN. Subjects with documented Gilbert disease are allowed if total bilirubin ≤ 3 x ULN
  • Adequate renal function defined by an estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula
  • Patients must be able to undergo MRI
  • Absence of active bacterial infection requiring antibiotic treatment
  • Karnofsky performance status ≥70
  • Primary tumor samples available for pathology review, central detection of T-cell responses in the peripheral blood and in the tumor tissue
  • No medical or social conditions that may interfere with trial outcome and follow-up

Who cannot join

  • Cardiovascular disease defined as:
  • Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)
  • Arterial thromboembolic event within 6 months before trial entry, including:
  • Myocardial infarction ii. Unstable angina pectoris iii. Cerebrovascular accident iv. Transient ischemic attack
  • Congestive heart failure New York Heart Association grade III to IV
  • Serious ventricular arrhythmia requiring medication and arrhythmias requiring Implantable Cardioverter Defibrillator (ICDs)
Show all 44Show fewer
  • Clinically significant peripheral artery disease > grade 2b according to Fontaine
  • History of intracranial hemorrhage
  • Hemoptysis within 6 months before trial entry
  • Known oesophageal varices
  • Upper or lower gastrointestinal bleeding within 6 months before inclusion (Day 0)
  • Significant traumatic injury or surgery within 4 weeks before trial entry
  • Non-healing wound, incomplete wound healing, bone fracture or gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion
  • Gastrointestinal fistula
  • Thrombolysis therapy within 4 weeks before trial entry
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that based on the investigator's judgement provides a reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the trial results or render the patient at high risk for treatment complications
  • Previous malignant disease (other than the tumor disease for this trial) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to trial entry and the subject was deemed to have been cured with no additional therapy required or anticipated to be required
  • Prior organ transplantation, including allogeneic stem cell transplantation
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent:
  • Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
  • Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable
  • History of uncontrolled intercurrent illness including but not limited to uncontrolled diabetes (e.g., hemoglobin A1c ≥ 8%)
  • Known prior hypersensitivity to investigational product or any component in its formulations or any other drug scheduled or likely to be given during the trial, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade ≥ 3)
  • Persisting toxicity related to prior therapy (NCI CTCAE v5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 AEs not constituting a safety risk based on investigator's judgment are acceptable
  • Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormalities that may increase the Risk associated with trial participation or trial treatment administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial
  • Active infection requiring systemic therapy
  • Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome or multi-drug resistant gram-negative bacteria
  • Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
  • Women of childbearing potential
  • History of serious ophthalmological diseases, e.g. optic neuropathy, retinal detachment, uveitis Prior and concomitant medication
  • Treatment in any other clinical trial within 30 days or within 5 half lives of any prior treatment, before screening
  • Any other condition or treatment that, in the opinion of the investigator, might interfere with the trial or current drug or substance abuse
  • Chronic concurrent therapy within 2 weeks before and during the treatment period with:
  • Corticosteroids (except steroids up to equivalent of dexamethasone 4 mg daily dose)
  • Immunosuppressive agents
  • Antibiotics
  • Bevacizumab or any other anti-angiogenic treatment
  • Any other anti-cancer therapy or concurrent anticancer treatment, for example, cytoreductive therapy, radiotherapy [with the exception of palliative short course, limited field (ie, ≤ 10 fractions and ≤ 30% bone marrow involvement or per institutional standard) radiotherapy, which may be administered during the study. However dosing must be suspended at least 14 days prior to the start of radiotherapy and must not be resumed until at least 14 days after the last radiotherapy fraction], immune therapy, or cytokine therapy, except for erythropoietin
  • Administration of live vaccines (other than VXM01) within 30 days prior to study treatment Other
  • Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines (other than VXM01)
  • Inability to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial
  • Unlikely to comply with the protocol requirements, instructions and trial-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial
  • Legal incapacity or limited legal capacity
  • Any condition which results in an undue risk for the patient during the trial participation according to the investigator

Trial locations and contacts

2 sites in 1 country.

Germany2 sites

  • Neurology Clinic and National Center for Tumor Diseases

    Heidelberg, 69120

  • Neurology Clinic

    Mannheim, 68167

Other trials in Germany

About this study

Official title: An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery

VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery

Read the detailed description

The trial is conducted as a multicenter, open-label, Phase I/II trial to evaluate the efficacy and safety of VXM01 in combination with avelumab in subjects with resectable and non-resectable progressive glioblastoma following tumor resection and radiochemotherapy containing temozolomide.

The trial will be performed in 30 subjects with progressive glioblastoma:

  • 24 subjects who will not be candidates for a tumor re-operation (non-resectable subjects)
  • 6 subjects who will be candidates for a tumor re-operation (resectable subjects) The trial, for each subject, will consist of a screening period, a treatment and observatioon phase of 60 weeks including, a treatment phase of up to 48 weeks with prime and boosting administrations of VXM01 in combination with avelumab and an observation phase of 12 weeks and with an end of trial visit at Week 60.

Subjects will receive VXM01 in combination with avelumab up to Week 48. The end of study (EoS) visit assessments will be performed Week 60.

Being tested
VXM01, Avelumab
Medical subject headings
Glioblastoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VXM01Biological

    Also called Investigational VEGFR-2 DNA Vaccine

    Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid

  • AvelumabBiological

    Also called Bavencio

    Monoclonal anti-PD-L1 Antibody

Study groups in NCT03750071
Study groupRoleWhat they receive
VXM01/AvelumabExperimentalCombination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
Receives: Biological: VXM01; Biological: Avelumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab)

    AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.

    Measured: Up to 60 weeks after first IMP administration

Secondary outcomes (6)

  1. Clinical response as assessed by time to progression (TTP)

    TTP is defined from the day of trial entry to the day of local tumor progression based on MRI (in days)

    Measured: Up to 60 weeks after first IMP administration

  2. Clinical response as assessed by progression free survival (PFS)

    PFS is defined from the day of trial entry to the day of local tumor progression or recurrence after reoperation, based on MRI, or further positive biopsy, or the day of death of any cause. Subjects free of progression/recurrence will be censored at the day of last tumor assessment (in days)

    Measured: Up to 60 weeks after first IMP administration

  3. Clinical response as assessed by recurrence-free survival after re-operation (RFS)

    RFS is defined from the day of trial entry to the day of recurrence after reoperation, based on MRI (in days)

    Measured: Up to 60 weeks after first IMP administration

  4. Clinical response as assessed by Overall Survival (OS)

    OSOS will be defined by death of any cause and subjects alive at trial end will be censored at last contact day (in days)

    Measured: Up to 60 weeks after first IMP administration

  5. Best overall response (OR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)

    The proportion of subjects with OR will be estimated together with 95% confidence intervals constructed using the binomial Distribution (in %)

    Measured: Up to 60 weeks after first IMP administration

  6. Duration of Response (DoR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)

    The DoR on MRI according to iRANO will be summarized descriptively for the two subgroups and illustrated using a Kaplan-Meier plot

    Measured: Up to 60 weeks after first IMP administration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2018
  2. Study start21 Nov 2018
  3. Primary completion31 Dec 2021
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03750071
Sponsor's protocol ID
VXM01-AVE-04-INT
Status last verified
Oct 2022
First submitted
26 Oct 2018
Last updated
20 Oct 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing VXM01 and Avelumab in people with Recurrent Glioblastoma, run by Vaximm GmbH at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 44 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab) (time frame: Up to 60 weeks after first IMP administration). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03750071.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2022; AzTrials last refreshed its copy on 1 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in